Market Research Logo

Obstructive Sleep Apnea - Pipeline Review, H2 2016

Obstructive Sleep Apnea - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obstructive Sleep Apnea – Pipeline Review, H2 2016, provides an overview of the Obstructive Sleep Apnea (Respiratory) pipeline landscape.

Obstructive sleep apnea is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. Signs and symptoms of obstructive sleep apnea include excessive daytime sleepiness, awakening with chest pain, morning headache, high blood pressure, awakening with a dry mouth. Risk factors include being overweight, hypertension, diabetes, gender, smoking and family history.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obstructive Sleep Apnea – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obstructive Sleep Apnea (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 2 respectively.Obstructive Sleep Apnea.

Obstructive Sleep Apnea (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Obstructive Sleep Apnea (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obstructive Sleep Apnea (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obstructive Sleep Apnea (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obstructive Sleep Apnea (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obstructive Sleep Apnea (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Obstructive Sleep Apnea Overview
Therapeutics Development
Pipeline Products for Obstructive Sleep Apnea - Overview
Obstructive Sleep Apnea - Therapeutics under Development by Companies
Obstructive Sleep Apnea - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Obstructive Sleep Apnea - Products under Development by Companies
Obstructive Sleep Apnea - Companies Involved in Therapeutics Development
Galleon Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc
SK Biopharmaceuticals Co Ltd
Vivus Inc
Obstructive Sleep Apnea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(phentermine + topiramate) ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dronabinol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GAL-475 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-N05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Obstructive Sleep Apnea - Dormant Projects
Obstructive Sleep Apnea - Discontinued Products
Obstructive Sleep Apnea - Product Development Milestones
Featured News & Press Releases
Sep 26, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea
Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA
May 14, 2015: VIVUS Announces Scientific Presentations
May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists
Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies
Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules
Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa
Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa
Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Obstructive Sleep Apnea, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Obstructive Sleep Apnea - Pipeline by Galleon Pharmaceuticals Inc, H2 2016
Obstructive Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016
Obstructive Sleep Apnea - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016
Obstructive Sleep Apnea - Pipeline by Vivus Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Obstructive Sleep Apnea - Dormant Projects, H2 2016
Obstructive Sleep Apnea - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Obstructive Sleep Apnea, H2 2016
Number of Products under Development by Companies, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report